On October 16, 2023 G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, reported that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Quality Care Symposium, held October 27th and 28th in Boston, MA (Press release, G1 Therapeutics, OCT 16, 2023, View Source [SID1234635997]). A copy of the posters will be made available on the G1 Therapeutics website following the presentations here.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The important research being presented at this year’s ASCO (Free ASCO Whitepaper) Quality Care Symposium highlights the significant burden of chemotherapy-induced myelosuppression and the real-world clinical impact of treatment with trilaciclib in patients with extensive-stage small cell lung cancer," said Raj Malik, M.D., Chief Medical Officer of G1 Therapeutics. "Real-world evidence is essential to deepening our collective understanding of the impact of treatment on patient outcomes."
Burden of Myelosuppression in Extensive-Stage Small-Cell Lung Cancer Patients Receiving Chemotherapy: Retrospective Analysis of Real-World Data from Tennessee Oncology. Blakely, L.J. et al.
Abstract 364. Poster Session A, Poster Board F21.
Friday October 27: 11:30 AM – 1:00 PM ET; 5:30 – 6:30 PM ET
Myelosuppression and Healthcare Utilization Among Patients with Chemotherapy-Treated Extensive-Stage Small Cell Lung Cancer (ES-SCLC) with and without Trilaciclib from Community Oncology Practices. Gajra, A. et al.
Abstract 527. Poster Session B, Poster Board L2.
Saturday, October 28: 7:00 AM – 8:00 AM; 11:45 AM – 1:00 PM ET
Assessment Of Hospitalizations and Cytopenia Events Among Patients with Extensive Stage Small Cell Lung Cancer (ES-SCLC) Receiving Chemotherapy with Trilaciclib. Huang, H. et al.
Abstract 531. Poster Session B, Poster Board L6.
Saturday, October 28: 7:00 AM – 8:00 AM; 11:45 AM – 1:00 PM ET
Patient Characteristics Associated with Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer Treated with Chemotherapy in The Community Oncology Setting. Goldschmidt, J. et al.
Abstract 289. Poster Session B, Poster Board J24.
Saturday, October 28: 7:00 AM – 8:00 AM; 11:45 AM – 1:00 PM ET